Cargando…

A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen

Prognosis for diffuse intrinsic pontine glioma (DIPG) and generally for diffuse midline gliomas (DMG) has only marginally improved over the last ~40 years despite dozens of chemotherapy and other therapeutic trials. The prognosis remains invariably fatal. We present here the rationale for a planned...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kast, Richard E., Michael, Alex P., Sardi, Iacopo, Burns, Terry C., Heiland, Tim, Karpel-Massler, Georg, Kamar, Francois G., Halatsch, Marc-Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016657/ https://www.ncbi.nlm.nih.gov/pubmed/31963414 http://dx.doi.org/10.3390/brainsci10010051

Ejemplares similares

Augmentation of 5-Aminolevulinic Acid Treatment of Glioblastoma by Adding Ciprofloxacin, Deferiprone, 5-Fluorouracil and Febuxostat: The CAALA Regimen
por: Kast, Richard E., et al.
Publicado: (2018)

CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
por: Kast, Richard E., et al.
Publicado: (2014)

The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy
por: Kast, Richard E, et al.
Publicado: (2017)

MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen
por: Kast, Richard E., et al.
Publicado: (2022)

Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen
por: Kast, Richard E, et al.
Publicado: (2017)

Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen
por: Salacz, Michael E, et al.
Publicado: (2016)

Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma
por: Pala, Andrej, et al.
Publicado: (2012)

In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma
por: Halatsch, Marc-Eric, et al.
Publicado: (2021)

DIPG-44. DIFFUSE MIDLINE GLIOMA WITH EXTRACRANIAL METASTASIS
por: Larsen, Alexandra Giantini, et al.
Publicado: (2023)

Ribozyme-Mediated Inhibition of 801-bp Deletion-Mutant Epidermal Growth Factor Receptor mRNA Expression in Glioblastoma Multiforme
por: Karpel-Massler, Georg, et al.
Publicado: (2010)

DIPG-46. TARGETING THE METABOLIC ERK5-PFKFB3 AXIS IN PEDIATRIC DIFFUSE MIDLINE GLIOMA
por: Casillo, Stephanie, et al.
Publicado: (2023)

DIPG-39. New preclinical models for Diffuse Midline Glioma
por: Klenner, Marbod, et al.
Publicado: (2022)

DIPG-06. Uncovering the FACTs in Diffuse Midline Glioma (DMG)
por: Holliday, Holly, et al.
Publicado: (2022)

A homogeneous treatment for non-DIPG diffuse midline glioma
por: Schiavello, Elisabetta, et al.
Publicado: (2022)

DIPG-47. HISTONE MUTATIONS ENHANCE RAS MEDIATED ERK5 GROWTH SIGNALING IN DIFFUSE MIDLINE GLIOMAS
por: Stanton, Ann-Catherine, et al.
Publicado: (2020)

DIPG-01. LIN28B EXPRESSION IN DIFFUSE MIDLINE GLIOMA
por: Knowles, Truman, et al.
Publicado: (2023)

DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY
por: Lafay-Cousin, Lucie, et al.
Publicado: (2020)

DIPG-17. BIOPSY-PROVEN DIFFUSE MIDLINE GLIOMA IN ADOLESCENTS AND YOUNG ADULTS
por: Tanaka, Shota, et al.
Publicado: (2020)

DIPG-22. TRIPTOLIDE AS A POTENTIALLY PROMISING THERAPY FOR DIFFUSE MIDLINE GLIOMA
por: Ciani, Ludovica, et al.
Publicado: (2023)

MJRA1.9 - AAI requirements of DCIs
Publicado: (Nove)

Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
por: Golla, Carolin, et al.
Publicado: (2021)

DIPG-04. THERAPEUTIC STRATEGY FOR DIFFUSE MIDLINE GLIOMAS. A SINGLE CENTER EXPERIENCE
por: Yamanaka, Takumi, et al.
Publicado: (2020)

DIPG-31. MOLECULAR MECHANISMS AND FUNCTIONAL IMPACT OF ABERRANT SPLICING IN DIFFUSE MIDLINE GLIOMAS
por: Naqvi, Ammar, et al.
Publicado: (2020)

DIPG-20. DELINEATING MEDIATORS OF ONCOGENESIS IN FOXR2-EXPRESSING DIFFUSE MIDLINE GLIOMAS
por: Tsai, Jessica, et al.
Publicado: (2023)

DIPG-09. ATOVAQUONE RADIOSENSITISES DIFFUSE MIDLINE GLIOMAS BY INHIBITING MITOCHONDRIAL METABOLISM AND HYPOXIA
por: Mudassar, Faiqa, et al.
Publicado: (2023)

Genome-wide identification of GhAAI genes reveals that GhAAI66 triggers a phase transition to induce early flowering
por: Qanmber, Ghulam, et al.
Publicado: (2019)

AAI-powered Federated Groups for SURF Research Drive
por: de Jong, Michiel
Publicado: (2023)

de.NBI Cloud federation through ELIXIR AAI
por: Belmann, Peter, et al.
Publicado: (2019)

DIPG-42. Diffuse midline gliomas, H3K27-altered as an interdisciplinary challenge
por: Kammler, Gertrud, et al.
Publicado: (2022)

DIPG-61. Preclinical efficacy of combined radiotherapy with venetoclax treatment in targeting diffuse midline gliomas
por: Madhavan, Krishna, et al.
Publicado: (2022)

DIPG-28. IDENTIFICATION AND TARGETING OF METABOLIC VULNERABILITIES IN COMBINATION WITH PDGFRA-INHIBITION IN DIFFUSE MIDLINE GLIOMA
por: Neyazi, Sina, et al.
Publicado: (2023)

Testing S3 API for OBS, and Federated AAI for HNSciCloud
por: Pintjuk, Daniil
Publicado: (2016)

DIPG-76. HISTONE H3 PHOSPHORYLATION IN H3K27M MIDLINE GLIOMAS
por: Zhang, Liang, et al.
Publicado: (2020)

DIPG-21. LINKING DETERMINATION OF CELL FATE IN THE DEVELOPING CENTRAL NERVOUS SYSTEM TO DIFFUSE MIDLINE GLIOMA
por: Furst, Liam, et al.
Publicado: (2023)

DIPG-11. DISSECTING THE DIFFUSE MIDLINE GLIOMA TUMOR MICROENVIRONMENT COMMUNICATIONS USING MULTI-OMICS APPROACHES
por: Collot, Raphael, et al.
Publicado: (2023)

Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma
por: Pruss, Maximilian, et al.
Publicado: (2020)

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

DIPG-44. H3K27-altered diffuse midline gliomas with secondary driver molecular alterations
por: Gestrich, Catherine, et al.
Publicado: (2022)

DIPG-02. A NOVEL STRATEGY TO RADIOSENSITISE DIFFUSE MIDLINE GLIOMAS VIA DUAL-TARGETING OF GLUCOSE METABOLISM
por: Shen, Han, et al.
Publicado: (2023)

DIPG-50. Bioinformatic evaluation of genes involved in sphingomyelin biosynthesis in Diffuse Midline Glioma H3K27 altered/DIPG: dysregulation of sphingosine 1-phosphate (SP1)
por: Humphreys, Aimee, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sbjurs3n4o8t2hp9lvnc39anv3